|
1. An injectable kit having component 1 and component 2, wherein the component 1 comprises carfilzomib or its pharmaceutical acceptable salts thereof, one or more solvent and optionally one or more pharmaceutically acceptable excipients selected from antioxidant, buffer, preservative and surfactant, wherein the concentration of carfilzomib or its pharmaceutically acceptable salts thereof in the component 1 is about 60 mg/ml and contains no more than 3% of total impurities upon storage of six months when stored at 25° C. and 60% relative humidity; and the component 2 is solution of acidifying agent having pH of about 1 to about 2.
|